Proactive Investors - Run By Investors For Investors

Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate

First-in-man studies of the ROCK2 technology will take place next year
picture of a liver
The drug will be given to people with NASH, or non-alcoholic liver disease

Redx Pharma Plc’s (LON:REDX) chief executive Lisa Anson said she was “encouraged” by pre-clinical data from a fibrosis drug set to enter human trials next year.

Three independent studies assessed the potential efficacy of the company’s lead ROCK2 compound in animal models of lung, kidney and liver fibrosis.

WATCH: Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate

The lab tests showed the Redx drug candidate was able to suppress collagen deposition and pathways associated with fibrosis, meaning it could have an impact on established forms of the disease.

Its profile suggests the putative treatment is suitable to be taken by mouth, rather than injected directly into the blood system.

Central role in fibrotic disease

ROCK2, or rho-associated coiled-coil containing protein kinase 2, is a protein that in humans regulates functions such as cell division and smooth muscle contraction.

It also plays a central role in metabolic and fibrotic disease, explained Dr Richard Armer, chief scientific officer of Redx.

“Generating highly selective ROCK2 inhibitors, without the significantly limiting hypotension observed with systemic use of existing non-selective ROCK1/2 inhibitors, has been a key research challenge,” he added.

“We are very encouraged to generate a highly selective ROCK2 inhibitor series where the lead compound has demonstrated anti-fibrotic effects pre-clinically in a broad range of organ models without any observed toxicity."

First-in-man studies

First-in-man studies of the ROCK2 technology will take place next year, focusing on people with NASH, or non-alcoholic liver disease.

“Liver fibrosis associated with NASH remains a condition with a clear unmet medical need and we hope that Redx's research into ROCK2 inhibition progresses into the clinic, potentially producing further data which could lead to a new treatment option for liver fibrosis patients," said CEO Anson.

The company’s most advanced and clinical-stage drug is a porcupine inhibitor. A phase I/II trial in people with solid tumours will re-start sometime in the first half.  

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use